NCT02807805View on ClinicalTrials.gov

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer

Interventions

DRUG

Abiraterone Acetate

Given PO

DRUG

Niclosamide

Given PO

DRUG

Prednisone

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mamta Parikh

OTHER

NCT02807805 - Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter